DeSilva Tara 4

What Happened

• Tara DeSilva, a director of Coeptis Therapeutics Holdings, reported two acquisitions on 2026-02-11: she exercised stock options (transaction code M) to acquire 5,700 shares at an exercise price of $10.56 each (total cash paid $60,192), and she was granted 3,250 restricted shares (transaction code A) with no cash cost reported.

Key Details

• Transaction dates and prices:
  • 2026-02-11: Exercise of options — 5,700 shares at $10.56/share (F1: $60,192 total).
  • 2026-02-11: Grant/award — 3,250 restricted shares at $0.00 (F2).
• Footnotes:
  • F1: $10.56 is the exercise price paid to purchase the shares.
  • F2: Restricted stock granted in connection with an option-exchange program; the reporting person surrendered underwater options in exchange for restricted stock.
• Shares owned after transaction: not specified in the information provided in your summary of the filing.
• Filing timeliness: Report filed 2026-02-13 for transactions on 2026-02-11 — appears timely under standard 2-business-day Form 4 rules (no late-file flag noted).
• No sale reported: the Form 4 shows shares were acquired, not sold or immediately cashed out.

Context

• Exercise of options (M) means the insider paid the exercise price to convert options into common shares. The award (A) reflects restricted stock issued as part of an option-exchange program, not a market purchase.
• These are acquisition events (potentially viewed as neutral-to-bullish signals), but they do not on their own indicate future company performance — they simply report insider ownership changes.